Highlights BenevolentAI

Equities

BAI

LU2355630455

Market Closed - Euronext Amsterdam Other stock markets 11:12:03 2024-05-31 am EDT			5-day change	1st Jan Change
0.56 ^EUR	-.--%		-2.78%	-48.15%

May. 15	BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected	CI
May. 02	Benevolentai S.A. Announces Directorate Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected	May. 15	CI
BenevolentAI Founder Reportedly Calls for Board Revamp	Apr. 02	MT
BenevolentAI Founder Reportedly Calls for Board Revamp	Apr. 02	MT
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	Apr. 02	AN
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers	Mar. 25	CI
BenevolentAI S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
EARNINGS: Symphony bemoans "weak global demand"; Aseana sells assets	23-09-26	AN
BenevolentAI S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
Merck Enlists 2 UK AI Companies to Collaborate on Drug Discoveries	23-09-20	MT
BenevolentAI Signs Strategic Collaboration with Merck	23-09-20	CI
BenevolentAI Doses First Participants in Clinical Trial of Ben-8744; Targets Pde10, an Ai-Derived Novel Target for the Treatment of Ulcerative Colitis	23-08-31	CI
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies	23-06-05	CI
BenevolentAI Announces New Preclinical Data on Ai-Generated Target Identified in Their Ongoing Collaboration with Astrazeneca	23-05-31	CI
Benevolentai S.A. Launches New Suite of Products	23-05-24	CI
BATM reports Edgility progress, Rambler starts sale	23-04-17	AN
BenevolentAI Announces Top-Line Results from Its Phase IIa, Randomised, Double-Blind, Placebo-Controlled Study of BEN-2293	23-04-05	CI
BenevolentAI société anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-16	CI
BenevolentAI société anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-16	CI
BenevolentAI Submits CTA for BEN-8744, as a First-In-Class Treatment for Ulcerative Colitis	22-12-21	CI
AstraZeneca Picks Two Additional Novel Target Drugs From BenevolentAI	22-10-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BenevolentAI

Equities

BAI

LU2355630455

Highlights

Filters